Foamix – Innovative, Versatile Topical Foams with IP protection
Press Release
Foamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, New Jersey, Sept. 28, 2016 /PRNewswire/ — Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $9.50 per share. Of the ordinary shares, 5,700,000 shares will be sold by Foamix and 300,000 shares will be sold by certain selling shareholders. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 900,000 additional ordinary shares . The offering is expected to close on Friday, September 30, 2016, subject to customary closing conditions.
Foamix
Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC is acting as lead manager.
A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on September 23, 2016. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may also be obtained, when available, from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 (888) 603-5847, email: Barclaysprospectus@broadridge.com; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone: (800) 221-1037, email: newyork.prospectus@credit-suisse.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631) 274-2806, fax: (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
Contact
Ilan Hadar
CFO
Foamix Pharmaceuticals Ltd.
+972-8-9316233
Ilan.hadar@foamixpharma.com
U.S. Investor Relations
Michael Rice
LifeSci Advisors, LLC
+1-646-597-6979
mrice@lifesciadvisors.com
Logo – http://photos.prnewswire.com/prnh/20160906/404614LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-ltd-announces-pricing-of-its-57-million-follow-on-offering-of-ordinary-shares-300335639.html
SOURCE Foamix Ltd